Vertex Pharmaceuticals IncorporatedVRTX

NasdaqGS•Healthcare•Biotechnology

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Price & Volume

Key Metrics at a Glance (as of December 2025)

Market Cap: $115.07B
TTM Revenue: $12.00B
TTM EBITDA: $2.61B
P/E Ratio: 29.1x
Operating Margin: 39.6%
Free Cash Flow: $361.70M

Financial Analysis

Vertex Pharmaceuticals Incorpor (VRTX) reported trailing twelve months (TTM) revenue of $12.00B as of December 2025, which represents a 8.9% increase year-over-year. The company's operating margin has expanded to 39.6% from 38.2% a year ago. In terms of profitability, VRTX generated $3.95B in net income. Valuation-wise, the stock trades at a P/E ratio of 29.1x and a Price-to-Sales (P/S) ratio of 9.6x. The company generated $361.70M in free cash flow over the last twelve months, indicating its ability to reinvest in growth or return capital to shareholders. Data based on the most recent quarterly reports.